Adlai Nortye Biopharma Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adlai Nortye Biopharma Co., Ltd.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
The selective PI3K inhibitor, alpelisib, met its primary PFS endpoint in top-line data from the SOLAR-1 study, but further details are needed from the trial in order to judge the drug's likely penetration of the HR-positive, HER2-negative breast cancer population.
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Scotlands ITI Life Sciences aims to create a unique model for plugging the widening funding gap between publicly funded research and venture-funded commercialization of technology. The firm's first four programs reflect the various ways it aims to drum up life sciences business in Scotland.
- Large Molecule